Early Onset of Response to Zasocitinib (TAK-279)

Name: Early Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis
Uploaded: 2026-03-31T04:00:00+00:00
Description: This video brief features Dr. April Armstrong reporting from the American Academy of Dermatology Annual Meeting 2026 in Denver on data from a phase 2b tria

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
This video brief features Dr. April Armstrong reporting from the American Academy of Dermatology Annual Meeting 2026 in Denver on data from a phase 2b trial of zasocitinib in patients with moderate-to-severe plaque psoriasis. Once-daily oral zasocitinib demonstrated early modulation of TYK2-mediated pathway genes, including IL-23 and type I IFN, and related skin lesion genes and serum biomarkers, which were associated with improved skin clearance at Week 4 and Week 12.
Provider(s)/Educational Partner(s)

It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.

April W. Armstrong, MD, MP

Recommended

Details

Presenters

Overview
This video brief features Dr. April Armstrong reporting from the American Academy of Dermatology Annual Meeting 2026 in Denver on data from a phase 2b trial of zasocitinib in patients with moderate-to-severe plaque psoriasis. Once-daily oral zasocitinib demonstrated early modulation of TYK2-mediated pathway genes, including IL-23 and type I IFN, and related skin lesion genes and serum biomarkers, which were associated with improved skin clearance at Week 4 and Week 12.
Provider(s)/Educational Partner(s)

It’s about time! Today’s on-the-go learners have minutes to spend on education instead of hours. Total CME is an award-winning, global healthcare education company that strategically pioneers methodology, initiatives, and platforms to meet these time-limited needs. Unlike other medical education companies, Total CME employs a microlearning approach and platform to create outcome-based curricula that motivates HCPs to engage in self-directed point-of-care learning that impacts change in real time. Even while reaching the largest global distribution, we provide the most personalized, seamless learner experience. We’re meeting our busy learners where they are so they can focus on what they want when they need it, ultimately leading to behavior changes that impact clinical practice and empower patients in their own care.
Commercial Support
This activity is supported by an independent educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.

April W. Armstrong, MD, MP

CME Learning Centers

CME/CE Topic Areas

Spotlight On:

Lifestyle

Trending Topics

Early Onset of Response to Zasocitinib (TAK-279), a Highly Selective and Potent TYK2 Inhibitor, Is Correlated With Modulation of TYK2 Signaling and Disease Pathway Biomarkers in Patients With Moderate-to-Severe Plaque Psoriasis

Provider(s)/Educational Partner(s)

Commercial Support

Disclaimer

Provider(s)/Educational Partner(s)

Commercial Support

Disclaimer

Program Chapters

Segment Chapters

Playlist:

Recommended

Transcript